By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

American Society of Hematology 

1900 M Street, NW, Suite 200

Washington  D.C.  20036  U.S.A.
Phone: 202-776-0544 Fax: 202-776-0545


SEARCH JOBS


Industry
Services






Company News
4 Massachusetts Biotechs Making Waves at American Society of Hematology 12/6/2016 5:57:35 AM
BerGenBio AS Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML At American Society of Hematology 2016 12/5/2016 3:14:02 PM
Acceleron Pharma And Celgene (CELG) Announce Updated Results From Ongoing Phase 2 Studies Of Luspatercept In Myelodysplastic Syndromes At The 58th Annual Meeting Of American Society of Hematology 12/5/2016 1:22:08 PM
Alexion (ALXN) Release: New Data From ALXN1210 Dose-Escalation Study Presented At American Society of Hematology Show Rapid And Sustained Reductions In LDH In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) 12/5/2016 1:16:57 PM
Acceleron Pharma And Celgene (CELG) Announce Preliminary Results From An Investigator Initiated Phase 2 Study Of Sotatercept In Myelofibrosis At The 58th Annual Meeting Of American Society of Hematology 12/5/2016 12:50:14 PM
Autolus Release: New CAR-T Approach For The Treatment Of T-Cell Lymphomas Presented At The 2016 American Society of Hematology Annual Meeting 12/5/2016 11:48:07 AM
Merck & Co. (MRK) Release: Updated KEYTRUDA (Pembrolizumab) Findings In Patients With Relapsed Or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented At 58th Annual Meeting Of The American Society of Hematology 12/5/2016 11:32:23 AM
Imara Presents Results For IMR-687, A PDE9 Inhibitor, In Sickle Cell Disease At American Society of Hematology 12/5/2016 11:29:29 AM
Syros Pharma Presents Data At American Society of Hematology Annual Meeting Further Supporting Clinical Potential Of Its First-In-Class Selective Rara Agonist For Genomically Defined Subsets Of AML And MDS Patients 12/5/2016 11:27:01 AM
Seattle Genetics (SGEN) Highlights Phase I Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy With HMAs, In Patients With Acute Myeloid Leukemia At American Society of Hematology Annual Meeting 12/5/2016 11:23:08 AM
12345678910...
//-->